Describes a number of important strategic decisions facing the scientific founder and CEO of a promising early stage bio-pharmaceutical company. Should the company to establish a planned alliance with a pharmaceutical company? Should there be a nutraceuticals business in parallel with its efforts to develop anti-aging therapies? And should there be a second drug development candidate licensee?

Describes a number of important strategic decisions facing the scientific founder and CEO of a promising early stage bio-pharmaceutical company. Should the company to establish a planned alliance with a pharmaceutical company? Should there be a nutraceuticals business in parallel with its efforts to develop anti-aging therapies? And should there be a second drug development candidate licensee?
«Hide

from
Toby Stuart,
James Webber
Source: Harvard Business School
10 pages.
Release Date: 4 October 2012. Prod #: 813 029 PDF-ENG
Sirtris Pharmaceuticals: living healthier, longer (shortened) HBR case solution

[related_post themes="flat"]